
Lilly Takes Full Control of Protomer Technologies
US drugmaker Eli Lilly has acquired Protomer Technologies, strengthening its diabetes portfolio. The deal gives Lilly full control over the privately held US biotech, having gained a 14% stake in Protomer last November following an equity investment alongside the JDRF T1D Fund – a venture philanthropy fund accelerating treatments for type 1 diabetes (T1D).






































